PCM Reports Record Fourth Quarter and Full-Year 2016 Results
Feb 08, 2017 21:03 pm UTC| Business
Record Profitability: Q4 EPS of $0.37 and Adjusted EPS of $0.51, Exceeding GuidanceRecord 2016 Full Year EPS of $1.40 and Adjusted EPS of $1.89 EL SEGUNDO, Calif., Feb. 08, 2017 -- PCM,Inc. (NASDAQ:PCMI), a leading...
Microchip Technology Incorporated Announces Proposed $2 Billion Offering of Convertible Notes
Feb 08, 2017 21:02 pm UTC| Business
CHANDLER, Ariz., Feb. 08, 2017 -- Microchip Technology Incorporated (NASDAQ:MCHP) (“Microchip”) today announced its intention to offer, subject to market conditions and other factors, $1.5 billion aggregate principal...
Fluidigm Announces Q4 and Full Year 2016 Financial Results
Feb 08, 2017 21:01 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 -- Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the fourth quarter and full year ended December 31, 2016. Total revenue for the fourth quarter...
Legacy Reserves LP Announces Year-End 2016 Conference Call
Feb 08, 2017 21:01 pm UTC| Business
MIDLAND, Texas, Feb. 08, 2017 -- Legacy Reserves LP ("Legacy") (Nasdaq:LGCY) today announced it intends to host a teleconference and webcast on Thursday, February 23, 2017, beginning at 9:00 a.m. Central Time to address...
Westell Delivers $2.9 Million Positive Cash Flow for Fiscal 3Q17
Feb 08, 2017 21:01 pm UTC| Business
AURORA, Ill., Feb. 08, 2017 -- Westell Technologies, Inc. (NASDAQ:WSTL), a leading provider of high-performance wireless infrastructure solutions, today announced results for its fiscal 2017 third quarter ended...
Insight Enterprises, Inc. Reports Fourth Quarter And Full Year 2016 Results
Feb 08, 2017 21:01 pm UTC| Business
TEMPE, Ariz., Feb. 08, 2017 -- Insight Enterprises, Inc. (Nasdaq:NSIT) (the “Company”) today reported results of operations for the quarter and full year ended December 31, 2016. Net sales up 6% to $1.47 billion for...
Fate Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference
Feb 08, 2017 21:01 pm UTC| Business
SAN DIEGO, Feb. 08, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that...